Welcome to Northwestern Medicine Antimicrobial and Diagnostic Stewardship
NM COVID-19 ResourcesPlease note: If using these resources, please understand this information will continue to change as the COVID-19 situation evolves in Chicago and across the United States.
Last updated: 5/6/22 Northwestern Medicine COVID-19 Treatment OptionsCOVID-19 Treatment Guidelines and Resources
No longer recommended due to increased prevalence of Omicron BA.1 & BA.2 variants As of 3.1.2022 As of 12.22.2021 Our MissionTo ensure that our patients receive the safest and most effective antimicrobial therapy for their infection while preserving and protecting the effectiveness of these endangered resources for future patients.
Clinician Antimicrobial Stewardship Training Resources
CDC Global Antimicrobial Resistance Challenge"Northwestern Medicine, an integrated academic health system in the Chicago area with 4,000 physicians and 30,000 employees caring for over 1.1 million patients, is committed to improving antibiotic use to ensure that these important medications remain effective treatment options. The Antimicrobial Stewardship Quality Committee commits to using local and CDC data to reduce unnecessary antibiotic use across their system. They also commit to increased use of penicillin allergy testing to remove misdiagnoses and decrease the use of broader-spectrum antibiotics. Utilizing both of these interventions will be aimed at reducing overly broad spectrum antibiotic use and emphasize their strong commitment to better patient care and combating antibiotic resistance."
See "Northwestern Medicine" on the CDC AMR Challenge Website 
|
System P&T UpdatesProtocol for Restricted Multi-Drug Resistant Gram-Negative Antibiotics
IV Metronidazole Alternatives C. difficile Infection Treatment Guidelines for Hospitalized Patients Vancomycin (IV) Dosing and Monitoring Guideline Biofire Blood Panel - Clinician Guidance
Pneumococcal Vaccination UpdateC. difficile Diagnostic AlgorithmNorthwestern Medicine has launched an updated Clostridioides difficile diagnostic algorithm across the healthcare system. Below are clinical decision support tools to guide providers through this transition.
FAQs: NM Diagnosis and Treatment of C. difficile Infection C. difficile Infection Testing Algorithm: PCR/Reflex Toxin EIA NMH Go-Live: 5/4/2021 All other sites, except Northwest Region: 7/24/2021 *subject to change, will update periodically Oral Cephalosporin RecommendationsCulture Decision AlgorithmsSafety Update: FluoroquinolonesNMH Allergy ToolkitRisk Assessment and Clinical Pathway
Graded Challenge Guidance Document Provider Education: Penicillin Allergy Cross Reactivity Chart: Beta-lactams 
|
